Physicians' Academy for Cardiovascular Education

PCSK9 inhibition in clinical lipid management: A critical review of evidence and opportunities

Meeting report with video, highlights and slides of PACE-CME symposium held during ESC 2016 in Rome on PCSK9 inhibition

Meeting Impression: PCSK9 inhibition at ESC 2016

PCSK9 INHIBITION IN CLINICAL LIPID MANAGEMENT: A CRITICAL REVIEW OF EVIDENCE AND OPPORTUNITIES

Oct. 2, 2016

During the ESC Congress 2016, held in Rome, Italy, PACE-CME organised a satellite symposium, in which the role of PCSK9 proteins in cardiovascular disease was discussed, as well as the emerging development of clinically potent PCSK9 inhibitors.

Preparing for a novel era in CV prevention

Where do PCSK9 inhibitors fit in lipid management?

Where do PCSK9 inhibitors fit in lipid management?
Where do PCSK9 inhibitors fit in lipid management?

Prof John Kastelein focussed his lecture on genetic dyslipidaemia, such as familiar hypercholesterolaemia(FH). FH is very prevalent in Western society and is estimated to occur in 1 in 200 people.

A clinical perspective on PCSK9 inhibition: What do we know and what can we expect?

Literature - Aug. 28, 2016 - Paul M Ridker, MD - Brigham and Women’s Hospital, Harvard Medical School, Boston, USA - PACE-CME symposium held at ESC 2016, Rome
A clinical perspective on PCSK9 inhibition: What do we know and what can we expect?

As of the discovery of statins in the prevention of CHD in 1994, treatment of cardiovascular (CV) disease and LDL-c reduction rapidly advanced. Today we have many potential new medications beyond statins and the question now is, should we use them, in whom and to what purpose.

PCSK9, the short track road from discovery as drug target towards the clinic

Presented by Gilles Lambert, MD, Université de la Réunion, Sainte-Clotilde, France

News - Aug. 27, 2016

According to Gilles Lambert the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a therapeutic target started with the LDL receptor (LDL-R). The LDL-R situates on the surface of most cell types, but most importantly on liver cells